Speaker Profile

M.D., Chief Medical Officer, Ultragenyx Gene Therapy and Inborn Errors of Metabolism

Dr. Crombez joined Ultragenyx following the acquisition of Dimension Therapeutics, a liver directed AAV gene therapy company. During his tenure at both companies, Dr. Crombez led the clinical development efforts for four clinical stage programs including gene therapy programs for hemophilia B, hemophilia A (in partnership with Bayer), ornithine transcarbamylase (OTC) deficiency and glycogen storage disorder type Ia (GSDIa). Dr. Crombez is also serving as an Industry Representative on the FDA Cellular, Tissue, and Gene Therapies Advisory Committee. Prior to this work in gene therapy, Dr. Crombez worked at Shire in their Human Genetics Therapy business unit for nearly eight years. Prior to joining industry, Dr. Crombez was Assistant Professor, Department of Pediatrics, Division of Medical Genetics at the David Geffen School of Medicine at the University of California, Los Angeles (UCLA).

 Session Abstract – PMWC 2022 Silicon Valley